Paracetamol 325mg / Isometheptene 65mg capsules
Available from a pharmacy with pharmacist advice
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Paracetamol + Isometheptene
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
MHRA licensed products
View all licensed products for Paracetamol + Isometheptene on the MHRA register
Midrid 325mg/65mg capsules
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Randomised trials: 1 · 1972–2026
Showing the 50 most relevant studies, sorted by most relevant.
Mario I. Ortiz, Gabriela Murguía-Cánovas, Laura C. Vargas-López, et al.
Medwave, 2016
Neha Parmar, Sandeep Singh Jadon, Ashish Mathur, et al.
Journal of Anesthesia & Pain Medicine, 2026
Background Effective postoperative pain management is an essential component of perioperative care. Preemptive analgesia, as a part of multimodal analgesic strategies, aims to reduce central sensitization and postoperative pain while minimizing opioid requirements. Paracetamol, diclofenac, and ketorolac are commonly used non-opioid analgesics; however, comparative evidence regarding their preemptive combinations remains limited. This study evaluated the efficacy of intravenous paracetamol alone, paracetamol–diclofenac, and paracetamol–ketorolac combinations in patients undergoing elective abdominal surgery under general anaesthesia. Methods In this prospective, randomized, double-blind study, 99 patients aged 20–60 years with American Society of Anesthesiologists (ASA) physical status I–II undergoing elective abdominal surgery were enrolled and randomly allocated into three equal groups (n = 33 each). Group P received intravenous paracetamol 1 g, Group PD received intravenous paracetamol 1 g plus diclofenac 75 mg, and Group PK received intravenous paracetamol 1 g plus ketorolac 30 mg before surgical incision. The primary outcome was time to first rescue analgesia. Secondary outcomes included postoperative pain intensity assessed using the Visual Analogue Scale (VAS), haemodynamic parameters, and incidence of adverse effects. Rescue analgesia was administered with intravenous tramadol when VAS was ≥4. Results Ninety-nine patients were randomized equally into three groups (n = 33 each). The primary outcome, time to first rescue analgesic requirement, differed significantly among the groups and was longest in Group PK (148.76 ± 15.39 min), followed by Group PD (113.27 ± 9.59 min) and Group P (95.52 ± 6.82 min) (F = 193.768, p < 0.001). Postoperative pain scores also demonstrated significant intergroup differences. Group PK showed lower VAS scores during the immediate postoperative period (0 h, 30 min, and 1 h), whereas Group PD demonstrated lower pain scores at 2 and 4 hours postoperatively. At later assessment intervals, both combination therapy groups maintained lower pain scores than paracetamol alone. Haemodynamic parameters remained stable and comparable among the groups. The incidence of postoperative adverse effects was low, with no statistically significant differences observed among the three groups. Conclusions Both paracetamol–ketorolac and paracetamol–diclofenac combinations provided superior postoperative analgesia compared with paracetamol alone in patients undergoing elective abdominal surgery under general anaesthesia. The paracetamol–ketorolac combination provided superior analgesia during the immediate postoperative period and significantly prolonged the time to first rescue analgesic requirement, whereas the paracetamol–diclofenac combination demonstrated superior analgesia during the intermediate postoperative period. Both multimodal analgesic regimens were associated with stable haemodynamic parameters and a favorable safety profile. These findings support the use of paracetamol–NSAID combinations as effective opioid-sparing strategies for postoperative pain management following elective abdominal surgery
Abstract licence: CC BY
Reactions Weekly, 2023
Reactions Weekly, 2024
Reactions Weekly, 2024
Reactions Weekly, 2023
Reactions Weekly, 2023
Reactions Weekly, 2024
Reactions Weekly, 2025
Reactions Weekly, 2023
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.